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Abstract
Objective: The influence hemostatitc parameters on the morphological extent and severity of
coronary artery disease were studied in patients with and without DM type 2.
Background: It is known that patients with diabetes (DM) have abnormal metabolic and
hemostatic parameters
Methods: Of 150 consecutive patients with angiographically proven coronary artery disease 29
presented with DM. Additionally to parameters of lipid-metabolism fibrinogen, tissue-
plasminogenactivator (t-PA), plasminogen-activator-inhibitor (PAI), plasmin-a-antiplasmin (PAP),
prothrombin-fragment 1+2 (F1+2), thrombin-antithrombin (TAT), von-willebrand-factor (vWF),
platelet factor 4 (PF4), glykomembranproteine 140 (GMP140) and the rheologic parameters plasma
viscosity and red blood cell aggregation were evaluated. The extent and severity of CAD was
evaluated according to the criteria of the American Heart Association.
Results: Patients with DM presented with a higher number of conventional risk factors as
compared to non-diabetic patients. Additionally there were significant differences for F1+2, red
blood cell aggregation and PAI. Diabetic patients showed a more severe extent of coronary
arteriosclerosis, which also could be found more distally. A significant relationship between blood-
glucose, thrombocyte-activation (vWF), endogenous fibrinolysis (PAI) and the severity of CAD and
a more distal location of stenoses could be found (r = 0.6, p < 0.001).
Conclusion: Patients with coronary artery disease and DM type 2 showed marked alterations of
metabolic, hemostatic, fibrinolytic and rheologic parameters, which can produce a
prothrombogenic state. A direct association of thrombogenic factors on coronary morphology
could be shown. This can be the pathophysiologic mechanism of more severe and distal
pronounced coronary atherosclerosis in these patients.
Published: 6 May 2009
Cardiovascular Diabetology 2009, 8:24 doi:10.1186/1475-2840-8-24
Received: 17 March 2009
Accepted: 6 May 2009
This article is available from: http://www.cardiab.com/content/8/1/24
© 2009 Jax et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 8
(page number not for citation purposes)
Cardiovascular Diabetology 2009, 8:24 http://www.cardiab.com/content/8/1/24Introduction
Coronary artery disease is the essential cardiac manifesta-
tion of diabetes mellitus type 2 and is responsible for the
predominant number of deaths. Early autopsy studies
pointed out, that the morphological manifestation of cor-
onary artery disease in patients with diabetes mellitus
increases three to four times as compared with non-dia-
betics [1-3]. The clinical relevance of these results is docu-
mented by an increased incidence of cardiovascular
events, and particularly in the "Framingham study" [4]
and in the following epidemiological and longitudinal
examinations [5,6]. The influence of diabetes mellitus is
statistically independent of other established risk factors
for the manifestation of coronary heart disease and is
regarded as the risk factor with the highest predictive value
for the incidence of cardiovascular complications
Since coronary thrombosis is essential for the pathogene-
sis of most acute coronary syndromes [7], the prothrom-
bogenic constellation is probably of importance for the
increased cardiovascular event rate among diabetics. Fur-
thermore it seems likely, that subclinical intracoronary
thrombi may promote atherosclerotic changes in patients
with coronary heart disease [8].
During the last few years increased attention has been
given to the complex metabolic changes associated with
diabetes mellitus type 2 and insulin resistance. In this
study, metabolic changes associated with diabetes, partic-
ularly changes of hemostasis and endogenous fibrinolysis
were studied. The importance with regard to the incidence
of cardiovascular events for diabetic patients was already
proven in large epidemiological studies [9-14]; the direct
association with morphological changes was not assessed
yet.
In the present study we test the hypothesis that a) diabetic
patients show a more diffuse form of coronary artery dis-
ease with a higher rate of distal stenosis and that b) hae-
mostatic parameters correlate with the extent of coronary
atherosclerosis in patients with diabetes mellitus type 2
Patients, material and methods
For this study 150 consecutive patients aged between 50
and 65 years, who were scheduled for elective coronary
angiography, were recruited at Heinrich-Heine-Univer-
sity, Division of Cardiology. Unstable angina pectoris,
acute myocardial infarction within the last six months
before inclusion into the study, and prior coronary inter-
ventions were exclusion criteria. Furthermore, patients
with acute or chronic infections and malignant diseases
were excluded. Patients with a diabetes type 1 were not
included in the study.
Definition of cardiovascular risk factors
Hyperlipidemia was defined as with total cholesterol
above 220 mg/dl, as triglycerides above 200 mg/dl, with a
positive history of hypercholesterolemia or hypertriglycer-
idemia and with lipid reducing therapies.
Diabetes was defined as fasting blood glucose above 126
mg/dl, or antidiabetic therapy. Hypertension was defined
as resting blood pressure above 140 mmHg systolic or 90
mmHg diastolic, or with antihypertensive medication.
Nicotine consumption was assessed by patient history.
Coronary Angiography
In all patients coronary angiograms with imaging of the
coronary arteries in different standardised projections
were carried out. The degree of coronary artery stenosis
was assessed by two experienced, independent examiners.
The severity of CAD was defined as coronary 1, 2 or 3 ves-
sel disease corresponding to the number of affected main
vessels with hemodynamic relevant stenosis above 50%.
Extent of coronary atherosclerosis was determined by a
special grading system in accordance with an evaluation
system of the American Heart Association [15]. Based on
these findings the coronary artery system was divided into
15 segments. The segment with a higher degree of stenosis
got a higher score. The sum of these scores was divided by
the number of judged segments. The result presents the
extent of coronary atherosclerosis. To get information
about the distribution pattern of coronary atherosclerosis
a proximal score from the proximal segments of coronary
main arteries and a distal score from the distal parts of
main coronary arteries and vessels of first degree were cal-
culated.
Laborchemical methods
Blood samples for the different parameters were taken at
the day of cardiac catheterisation between 7:00 and 8:00
am after 30 minutes rest in a lying position. Venous punc-
ture of an antecubital vene was done with a butterfly can-
ula after a maximum venous compression time of 30
seconds and a maximum pressure of 40 mmHg. After
decompression the first 4 ml of blood were not used. For
parameters of hemostasis and endogenous fibrinolysis
vacutainer tubes with 0.129 M Na2 citrat were used. Tubes
underwent centrifugation at 2000 g for 15 minutes. The
plasma was taken and centrifugated at 2000 g for another
15 minutes. Samples were frozen at -80°C. The samples
were analysed immediately after preparation from deeply
frozen plasma within three months after sample taking.
Determination of plasma viscosity and red blood cell
aggregation was performed from EDTA tubes within 4
hours after sample taking. Plasmaviscosity was deter-Page 2 of 8
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Aachen (Germany). For determination of red blood cell
aggregation an erythrocyte aggregometer (Myrenne, Roet-
gen, Germany) was used.
Plasma fibrinogen levels were determined according to
method described by Clauss [16]. Prothrombin fragment
1 and 2 were measured by Elisa. Specific activity of AT III
was measured by a cinetic test; Protein C and S were meas-
ured by coagulometric tests. Determination of Plasmino-
genactivator inhibitor activity was performed by
chromogenic enzymassay. Thrombin-Antithrombin III
complex, plasma tissue plasminogenactivator antigen
concentration, plasmin a2 antiplasmin and d-dimeres
were determined by enzymimmunoassay.
Obesity indices
As a calculated index to estimate the extent of Obesity the
"body mass index" is clinically established. This index cal-
culates itself by the body weight (kg) being divided by the
square of the height (m2). The relationship between
waists and hip circumference forms another parameter for
the classification of obesity [17]. This quotient was shown
to correlate with the visceral fat mass [18].
Statistical methods
Statistical analyses were performed using SPSS software
(Statistical Package for Social Sciences for Windows; SPSS
12.0, Munich). The results were tested for normal distri-
bution by Kolmogoroff-Smirnoff test. For normally dis-
tributed parameters group comparison was made by use
of paired and unpaired Student's t-test. Mann-Whitney U-
Test was used for non-normally distributed parameters.
The Pearson correlation coefficient or the Spearman's
rank correlation was used to describe the association
between the variables in the study. A stepwise regression
model was used to test the relationship of laboratory
parameters on morphology. Chi square test was used for
comparison of non-continuous data. Statistical signifi-
cance was defined as p < 0.05.
Results
Out of 150 consecutive patients, 28 patients presented
with the diagnosis of diabetes mellitus type 2 (19%). Both
groups showed a comparable age profile, they were not
different with regard to height, however, diabetic patients
were heavier, what resulted in a significantly higher "body
mass index". Both waist circumference and the "Waist-to
hip ratio" calculated from this differed significantly.
Diabetic patients showed a 20% higher rate of arterial
hypertension (table 1). Other conventional risk factors
did not differ between the groups (table 1). The laboratory
evaluation showed that only HDL cholesterol differed sig-
nificantly, although the differences for triglycerides are
only not significantly different because of the wide stand-
Table 1: Patient characteristics
all patients
(n = 150)





age (years) 58 ± 5 57 ± 4 58 ± 5 0.1158
hypertension (%) 62.0% 85.00% 57.00% 0.0076
hypercholesterinemia (%) 74.0% 73.00% 74.00% 0.9419
hypertriglyceridemia(%) 40.0% 46.00% 39.00% 0.47068
smoking (%) 10.0% 4.00% 11.00% 0.28139
ex-smoking (%) 75.0% 81.00% 74.00% 0.4543
history of vascular diesease (%) 31.0% 39% 30.00% 0.37048
obesity (%) 83.0% 100% 80.00% 0.01134
Hyperurikämie (%) 20.0% 12% 22.00% 0.26987
total cholesterol (mg/dl) 226 ± 42 225 ± 50 225 ± 40 0.5254
HDL – cholesterol (mg/dl) 44 ± 13 37 ± 10 46 ± 14 0.0035
LDL – cholesterol (mg/dl) 157 ± 39 159 ± 45 156 ± 37 0.9246
triglycerides (mg/dl) 210 ± 141 239 ± 189 205 ± 130 0.4681
lipoprotein (a) (mg/dl) 20,4 ± 22,5 16,1 ± 21,9 20,7 ± 22,1 0.1302
uric acid (mg/dl) 6,3 ± 1,5 6,4 ± 1,6 5,6 ± 1,1 0.0341
fasting plasma glucose (mg/dl) 116 ± 51 197 ± 75 100 ± 19 0.0001
Insuline (mU/l) 8,8 ± 5,7 8,7 ± 4,7 8,8 ± 5,9 0.7382
HbA1c (%) 6,0 ± 1,3 8,1 ± 1,5 5,5 ± 0,6 0.0001
heigth 174 ± 6 173 ± 7 174 ± 6 0.4923
weight (kg) 83 ± 12 85 ± 10 82 ± 12 0.171
Body-Mass-Index (kg/m2) 27,35 ± 3,42 28,42 ± 2,78 27,12 ± 3,51 0.0367
Waist-to-Hip-Ratio 0,99 ± 0,07 1,03 ± 0,07 0,98 ± 0,07 0.0035
waist circumference (cm) 99 ± 9 104 ± 9 100 ± 6 0.0079
hip circumference (cm) 100 ± 6 100 ± 7 100 ± 6 0.6175Page 3 of 8
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were markedly elevated in diabetic patients, as expected;
there was no difference in fasting insulin levels.
Patients with diabetes mellitus type 2 showed higher val-
ues for fibrinogen, the difference, however, was not signif-
icant (table 2). Also, prothrombin fragments 1 and 2 as
indicators for a thrombin synthesis and a marker for pro-
thrombotic conditions, was elevated in patients with dia-
betes mellitus, although again, not significantly.
Anthrombin III and D-dimer showed no statistical signif-
icant differences (table 2). Plasma viscosity and aggrega-
tion of erythrocytes as the essential variables influencing
microcirculation were higher in patients with diabetes
mellitus. Of the markers of fibrinolysis PAI activity was
significantly higher in patients with diabetes. Thrombo-
cytic parameters did not differ at all between the two
groups.
Patients with diabetes more often presented with 3 vessel
disease (table 2). The evaluated coronary score was signif-
icantly higher in patients with than without diabetes mel-
litus. Patients with diabetes especially showed a higher
distal score.
The plasma levels of insulin and HbA1c correlated on the
one hand significantly with PAI activity and tPA concen-
tration, on the other hand also with indices of obesity
(table 3). Of the parameters of lipid metabolism only trig-
lycerides correlated with insulin. Fasting glucose on the
day of coronary angiography strongly correlated with the
total and the distally weighted score (R = 0.48, table 3).
We then calculated a univariant regression model for each
of the three coronary scores and parameters of lipid and
glucose metabolism, hemostasis and fibrinolysis, platelet
activation, rheology, obesity and hypertension. Results
are given in table 4. All significant parameters were
included into a multivariate, stepwise regression analysis.
This analysis revealed the most significant correlation
between fasting glucose and all coronary scores but in par-
ticular with total and distal score, followed by waist to hip
Table 2: Parameters of hemostasis, rheology, fibrinolysis, platelet activation and extent and severity of coronary atherosclerosis
all patients Diabetes mellitus Typ II control patients p-value
(n = 150) (n = 26) (n = 122)
hemostasis
fibrinogen (mg/dl) 282 ± 64 295 ± 76 278 ± 61 0.1618
prothrombinfragment 1 + 2 (μg/dl) 0,99 ± 0,52 1,01 ± 0,55 0,87 ± 0,37 0.0622
D-Dimere (μg/l) 35 ± 62 31 ± 43 36 ± 65 0.5519
Thrombin-Antithrombin-Komplex (μg/l) 7,6 ± 16 9,6 ± 18,7 7,3 ± 15,5 0.5221
Rheology
plasma viscosity (mPas) 1,30 ± 0,09 1,33 ± 0,09 1,29 ± 0,09 0.0933
erythocyte aggregation M (E) 6,3 ± 1,8 7,3 ± 1,9 6,1 ± 1,8 0.0026
erythocyte aggregation M1 (E) 11,3 ± 2,5 12,8 ± 2,7 11,0 ± 2,3 0.0013
hematocrit (%) 43,5 ± 3,1 42,7 ± 3,7 43,6 ± 2,9 0.1537
fibrinolysis
tissue-plasminogenaktivator (ng/dl) 13,47 ± 3,68 14,18 ± 3,36 13,30 ± 3,77 0.4394
plasminogenactivatorinhibitor (U/ml) 5,78 ± 3,25 7,36 ± 3,24 5,45 ± 3,18 0.0017
plasmin-α2-antiplasmin-complex (μg/dl) 395 ± 152 378 ± 168 396 ± 146 0.4245
platelet activation
platelet count (100.000/ml) 246 ± 71 265 ± 71 242 ± 71 0.1727
von Willebrand-factor (μg/l) 94 ± 31 99 ± 32 93 ± 30 0.3661
plateletfactor 4 (μg/l) 12,7 ± 18,8 9,2 ± 10,9 13,4 ± 20,1 0.9104
β-thromboglobulin (μg/l) 36,68 ± 41,90 30,07 ± 17,57 38,28 ± 45,53 0.7181
GMP 140 (μg/l) 96,36 ± 44,69 94,64 ± 23,41 96,88 ± 48,26 0.2773
Extent and severity of coronary atherosclerosis
total score 1,451 ± 0,591 1,858 ± 0,680 1,379 ± 0,550 0.0182
proximal score 1,399 ± 0,696 1,775 ± 1,037 1,333 ± 0,607 0.2363
distal score 1,457 ± 0,666 1,874 ± 0,647 1,388 ± 0,651 0.0109
1-vessel CAD 31.0% 12.0% 35.0%
2-vessel CAD 37.0% 39.0% 37.0%
3-vessel CAD 32.0% 50.0% 28.0% 0.0306Page 4 of 8
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brand factor for total score (table 4)
Discussion
Coronary morphology in diabetes mellitus
Although it is well established, that type 2 diabetes is a
strong and independent risk factor for the development of
atherosclerosis, there is much discussion about a "typi-
cal", diabetes related morphology of atherosclerosis.
Many clinicians today believe, that diabetic patients
present with more extensive atherosclerotic disease than
non-diabetics. However, to our knowledge only very few
studies confirm these subjective impressions, and these
are mostly autopsy based. Early autopsy studies pointed
out, that the morphological manifestation of coronary
artery disease in patients with diabetes mellitus increases
three to four times as compared with non-diabetics [1-3].
Here, we present a systematic approach to evaluate the
coronary morphology of consecutive patients by angiog-
raphy with regard to their diabetic status and can confirm
this widespread belief. Coronary atherosclerosis can be
found in more segments and is generally located more dis-
tally. This also confirms the results of a recent study,
which could show a higher extent of coronary plaque bur-
den in diabetic patients [19]. Recent studies using intra-
vascular ultrasound (IVUS) to evaluate coronary plaque
burden in diabetic patients could show more extensive
atherosclerosis [20-22]. However, these studies are often
technically limited and can not be used to assess distal
segments. Nicholls and co-workers assessed IVUS and also
quantitative coronary angiography (QCA) and could not
find a correlation between diabetes and stenosis severity.
However, QCA was only done in segments also evaluated
by intravascular ultrasound and did only comprise the
most severe stenosis per target vessel [22]. They did find
diabetes to be a strong independent predictor of athero-
sclerotic coronary disease, but the distribution of athero-
sclerosis within the coronary arteries was not assessed. An
analysis of pooled data revealed that coronary artery
atherosclerosis in patients with diabetes mellitus is more
extensive and accompanied by inadequate compensatory
remodelling [23]. Additionally the progression of
atheroma was more rapid in patients with diabetes,
despite high use of well established and potent therapies.
With this in mind angiographic assessment could under-
estimate the plaque burden. On the other hand recent
studies suggest, that a high percentage of cardiac patients
present with newly diagnosed type 2 diabetes by use of
oral glucose tolerance tests (OGTT) [24-26]. OGTT was
not part of this protocol; therefore the true rate of diabetes
may be underestimated.
Hemostasis and fibrinolysis in diabetes mellitus
Type 2 diabetes mellitus, most often being part of a meta-
bolic syndrome is closely associated with obesity, periph-
eral insulin resistance, arterial hypertension,
hypercholesterinemia, hypertriglyceridemia and predis-
poses for atherosclerosis [27]. Peripheral insulin resist-
ance is strongly associated with atherosclerosis, even after
adjusting for other more conventional risk factors [28].
Whether this relation is causal, can only be suspected
[28,29], other authors discussed whether an impaired
fibrinolysis could be the link to atherosclerosis [30].
The changes of hemostasis and endogenous fibrinolysis of
diabetic patients in this study correspond with the litera-
ture [9-13,30], although most often only single parame-
ters were evaluated. These alterations might be
responsible for higher atherogenicity and more cardiovas-
cular events in a diabetic population.
Table 3: The Pearson correlation coefficient or the Spearman's rank correlations were used to describe the association between the 
variables in the study.
tPA PAI cholesterol HDL LDL tg fibrinogen plasmaviscosity
insuline 0.3173 0.2573 0.0112 -0.152 0.0304 0.2702 -0.0011 0.0444
0.008 0.002 0.896 0.076 0.725 0.001 0.99 0.612
HbA1c 0.2941 0.4117
0.016 0.0001
insuline HbA1c HDL LDL
WHR 0.2716 0.2903 -0.3765 0.3134
0.033 0.014 0.002 0.009
C-Index 0.4067 0.4429 -0.3539 0.1792
0.001 0.0001 0.004 0.153
total score prox. score dist. score
glucose 0.4872 0.2097 0.4769
0.0001 0.108 0.4769
Upper line denotes R, lower line the according p-valuePage 5 of 8
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(PAI) was increased in diabetic patients; this corresponds
to other studies [12,14,31,32]. Additionally we found a
strong correlation between PAI and insulin levels, which
confirms results from experimental studies, where insulin
decreased PAI activity in a dose dependent manner
[12,33].
The potential role of insulin as one of the mechanisms in
atherogenesis in diabetic patients has been discussed for
25 years [34]. Results of various prospective studies indi-
cated that elevated plasma insulin levels cause and
enhance atherosclerosis [35-37]. Diverse diseases associ-
ated with hyperinsulinemia show an early and extended
manifestation of atherosclerosis [38-43]. Several studies
proved that elevated insulin levels are accompanied by
reduced endogenous fibrinolysis [12,14,31]. On the one
hand hyperinsulinemia is associated with a decreased t-PA
concentration [11], on the other hand it causes an
increase of PAI activity [12-14,31].
Table 4: univariant and multivariant (stepwise backward) regression model for each of the three coronary scores and parameters of 
lipid and glucose metabolism, hemostasis and fibrinolysis, platelet activation, rheology, obesity and hypertension.
total score distal score proximal score
Univariat Multivariat Univariat Multivariat Univariant
R p-value R p-value p-value R p-value
Conventional risk factors
Total cholesterol (mg/dl) 0,17099 0,1665 0,15137 0,2214 0,12198 0,3254
HDL – cholesterol (mg/dl) 0,1864 0,134 0,21858 0,0779 0,3475 0,02781 0,8246
LDL – cholesterol (mg/dl) 0,11409 0,3617 0,08219 0,5118 0,11332 0,365
Triglycerides (mg/dl) 0,00269 0,9827 0,00918 0,9412 0,02211 0,8591
Uric acid (mg/dl) 0,28913 0,0205 0,2187 0,28087 0,0246 0,1682 0,16794 0,2011
Plasma glucose (mg/dl) 0,5456 0,0001 0,0001 0,47045 0,0001 0,0001 0,42108 0,0005
Insuline (mU/l) 0,01736 0,8943 0,01917 0,8834 0,10553 0,4182
HbA1c (%) 0,13988 0,2589 0,14837 0,2308 0,02186 0,8606
Hemostasis
Fibrinogen (mg/dl) 0,07329 0,5556 0,07759 0,5326 0,03252 0,7939
Prothrombinfragment 1+ 2 (μg/l) 0,05127 0,6803 0,05278 0,6715 0,00098 0,9937
D-dimers (μg/l) 0,22375 0,0687 0,19556 0,1127 0,19572 0,1124
Thrombin-Antithrombin-complex 0,11095 0,3714 0,10142 0,4141 0,07338 0,5551
tissue-Plasminogenactivator (ng/dl) 0,09567 0,4913 0,07875 0,5714 0,08 0,5653
Plasminogenactivatorinhibitor (U/ml) 0,22549 0,0666 0,1947 0,25669 0,036 0,0407 0,03477 0,78
Plasmin-a2-Antiplasmin-complex (μg/dl) 0,08721 0,4828 0,08614 0,4882 0,05627 0,6511
Platelet parameters
von Willebrand-Factor (μg/l) 0,3335 0,0058 0,013 0,32558 0,0072 0,2661 0,2229 0,698
Platelet factor 4 (μg/l) 0,00077 0,9951 0,02395 0,8486 0,6825 0,5861
β-Thromboglobulin (μg/l) 0,08704 0,4871 0,05816 0,6428 0,11954 0,339
GMP 140 (μg/l) 0,11087 0,3718 0,10535 0,3962 0,07522 0,5452
Rheological parameters
Plasma viscosity (mPas) 0,05615 0,6518 0,07809 0,5299 0,0132 0,9156
Erythrocyte aggregation M (E) 0,00747 0,9552 0,02073 0,8761 0,02058 0,8771
Erythrocyte aggregation M1 (E) 0,02564 0,8471 0,04427 0,7392 0,034 0,7982
Obesitys-Indices
BMI (kg/m2) 0,07228 0,561 0,06516 0,6003 0,06279 0,6137
WHR 0,18316 0,165 0,24149 0,0654 0,0003 0,00075 0,9955
Waist (cm) 0,02086 0,8799 0,01037 0,9401 0,05692 0,6798
Hip(cm) 0,00135 0,9922 0,00294 0,983 0,02922 0,8323
Blood pressure
systolic (mm Hg) 0,14903 0,2287 0,14472 0,2426 0,10775 0,3855
diastolic (mm Hg) 0,10406 0,402 0,05629 0,6509 0,16688 0,1771
mean (mm Hg) 0,1775 0,1507 0,13861 0,2633 0,19968 0,1052Page 6 of 8
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of men after primary myocardial infarction. Those
patients who showed elevated PAI concentrations as a
sign of reduced fibrinolysis were at increased risk of reinf-
arction [44,45]. High concentrations of von Willebrand
factor antigen are supposed to be markers of endothelial
lesions and present a procoagulative mechanism due to
an enhanced platelet adhesion [46].
The question remains, how does diabetes mediate its spe-
cific effects towards a diabetic specific morphology? Some
authors suggest that diabetics undergo invasive evaluation
later than others due to their cardiac neuropathy and the
resulting lack of symptoms, others, that the impact of the
often combined risk factors (e.g. hypertension, high LDL
etc.) may trigger an accelerated form of atherosclerosis.
This study extends these views by showing a close associ-
ation between coronary morphology and a diabetic status
with alterations of haemostasis and fibrinolysis, especially
for distal coronary artery disease. Univariate and multivar-
iate regression analysis revealed a strong relationship
between the extent of coronary and especially distal coro-
nary atherosclerosis and fasting glucose, PAI-1 and von-
Willebrand-factor.
Conclusion
Both parameters of endogenous fibrinolysis and markers
of platelet activity showed a relevant association on the
extent of coronary atherosclerosis. This association
applied to both the total and in particular to the distally
weighted coronary atherosclerosis score. Additional pre-
disposing factors were increased uric acid and glucose
concentrations as well as the "Waist hip ratio". These
changes are part of the "metabolic syndrome" describing
obesity, arterial hypertension and typical changes of glu-
cose and lipid metabolism, hemostasis and fibrinolysis.
The metabolic changes with imbalance of platelet activity,
hemostasis and endogenous fibrinolysis, and rheology
favour a prothrombotic milieu. These systemic changes
may result in an increased, thrombosis driven atheroscle-
rotic process, in part explaining the advanced coronary
plaque burden and in particular the more distal pro-
nounced distribution of coronary atherosclerosis in
patients with diabetes. More research is needed to eluci-
date these potential mechanisms and possibly develop a
tailored therapy for these diabetes specific mechanisms of
atherothrombotic disease.
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